Keros Therapeutics (KROS)
Develops protein therapeutics for neuromuscular disease and blood-cell disorders.
$11.63
vs last close−0.10 (−0.85%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 94.38% | 18.71M shares | |
|---|---|---|---|
| 134 holders · as of Jun 30, 2026 | |||
| Insiders | 9.35% | 1.85M shares | |
| 17 holders · as of Aug 20, 2026 | |||
| Strategic holders | 23.36% | 4.63M shares | |
| 1 holder · as of Oct 17, 2025 | |||
| Adds to | 127.09% | ||
19.83M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 127.09%; nothing is left for Other.
13F, as of Jun 30, 2026
134 holders · 18.71M shares · 16 new positions · 62 increased · 51 reduced · 33 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 2.79M | 14.09% | +382.4K | Aug 7, 2026 |
| Nantahala Capital Management, LLC | 1.41M | 7.11% | +50.0K | Aug 19, 2026 |
| AQR Capital Management LLC | 967.9K | 4.88% | +561.3K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 833.6K | 4.20% | +2.2K | Aug 13, 2026 |
| Orbimed Advisors LLC | 759.2K | 3.83% | 0 | Aug 14, 2026 |
| Federated Hermes, Inc. | 700.4K | 3.53% | +11.2K | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 652.6K | 3.29% | −29.4K | Aug 13, 2026 |
| Mackenzie Financial Corp | 628.4K | 3.17% | +476.0K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.10% | 1.99M | 13G | Apr 7, 2026 |
| Nantahala Capital Management, LLC | 6.90% | 1.36M | 13G | May 15, 2026 |
| Madison Avenue Partners, LP | 6.40% | 2.61M | 13G | May 14, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Charles W. Newtondirector | Sale | 551 | $10.30 | 12,114 |
| Aug 18, 2026 | Esther Choofficer: Chief Legal Officer | Sale | 4,485 | $10.29 | 35,770 |
| Aug 18, 2026 | Lorena Raquel Lernerofficer: Chief Scientific Officer | Sale | 3,568 | $10.29 | 27,559 |
| Aug 18, 2026 | Annita Taniniofficer: Corp. Controller & VP, Finance | Sale | 1,224 | $10.29 | 45,144 |
| Aug 17, 2026 | Jean Jacques Bienaimedirector | Purchase | 1,000 | $10.27 | 19,592 |
| Jul 15, 2026 | Jean Jacques Bienaimedirector | Purchase | 1,000 | $10.61 | 18,592 |
| Jun 15, 2026 | Jean Jacques Bienaimedirector | Purchase | 1,000 | $10.19 | 17,592 |
| Jun 11, 2026 | Charles W. Newtondirector | Sale | 550 | $10.04 | 12,665 |
| Jun 4, 2026 | Julius Knowlesdirector | Sale | 2,625 | $10.73 | 10,958 |
| Jun 4, 2026 | Nima Farzandirector | Sale | 2,625 | $10.73 | 9,767 |
House and Senate disclosures
Not reported.